Jin Ng, PhD (@jinng_1) 's Twitter Profile
Jin Ng, PhD

@jinng_1

Senior Research Officer / Post-doc in Lung Cancer @wehi_research @sutherland_lab | 🏳️‍🌈 🇦🇺 🇲🇾 views are my own (he/him)

ID: 1141650537596608512

calendar_today20-06-2019 10:14:33

160 Tweet

439 Followers

584 Following

Jin Ng, PhD (@jinng_1) 's Twitter Profile Photo

⚡️Excited to share that our research proposal around novel #immunotherapy approaches for small cell lung cancer was awarded a grant through Cancer Council Victoria Grants-In-Aid together with Sutherland Lab Fern Koay 郭 Nick Gherardin ⚡️ Read more: cancervic.org.au/downloads/rese…

Jin Ng, PhD (@jinng_1) 's Twitter Profile Photo

Incredibly grateful for Clinical Cancer Research Translations piece by Natasha Rekhtman MD PhD Memorial Sloan Kettering Cancer Center on our recent work demystifying identity of "SCLC-Y" cell lines. Sutherland Lab Marian Burr 🔽Natasha's commentary: doi.org/10.1158/1078-0… 🔽Original article: doi.org/10.1158/1078-0…

Incredibly grateful for <a href="/CCR_AACR/">Clinical Cancer Research</a> Translations piece by <a href="/natasharekhtman/">Natasha Rekhtman MD PhD</a> <a href="/MSKCancerCenter/">Memorial Sloan Kettering Cancer Center</a> on our recent work demystifying identity of "SCLC-Y" cell lines.
 
<a href="/Sutherland_Lab/">Sutherland Lab</a> <a href="/Burr_Lab/">Marian Burr</a> 

🔽Natasha's commentary:
doi.org/10.1158/1078-0…

🔽Original article:
doi.org/10.1158/1078-0…
Doherty Institute (@thedohertyinst) 's Twitter Profile Photo

Congratulations Fern Koay 郭 for receiving a CASS Foundation Medicine/Science Grant, to support her work testing unconventional T cell-based strategies for cancer immunotherapies. doherty.edu.au/news-events/ne… UniMelb MDHS The Royal Melbourne Hospital

Stephen V Liu, MD (@stephenvliu) 's Twitter Profile Photo

#ELCC24 Poster describing outcomes with 2L therapy after 1L chemo-immunotherapy in #SCLC. 31% lurbinectedin, 21%, EP rechallenge, 9% topotecan. Survival similar in rechallenge vs other. Only 23% go on to 3L. #ESMOAmbasaadors ESMO - Eur. Oncology IASLC

#ELCC24 Poster describing outcomes with 2L therapy after 1L chemo-immunotherapy in #SCLC. 31% lurbinectedin, 21%, EP rechallenge, 9% topotecan. Survival similar in rechallenge vs other. Only 23% go on to 3L. #ESMOAmbasaadors <a href="/myESMO/">ESMO - Eur. Oncology</a> <a href="/IASLC/">IASLC</a>
Jin Ng, PhD (@jinng_1) 's Twitter Profile Photo

Posting ahead of International Transgender Day of Visibility (tdov.org.au) 31 Mar 24 WEHI (Walter and Eliza Hall Institute) Illuminarium lit up in support! Trans people have unique challenges w/ cancer journey Cancer Council Victoria. Collective work & allyship needed cancervic.org.au/cancer-informa…

Posting ahead of International Transgender Day of Visibility (tdov.org.au) 31 Mar 24 <a href="/WEHI_research/">WEHI (Walter and Eliza Hall Institute)</a> Illuminarium lit up in support!

Trans people have unique challenges w/ cancer journey <a href="/CancerVic/">Cancer Council Victoria</a>. Collective work &amp; allyship needed

cancervic.org.au/cancer-informa…
Natasha Rekhtman MD PhD (@natasharekhtman) 's Twitter Profile Photo

If you like to read final versions - this was just posted: Commentary on SMARCA4-deficient undifferentiated tumors mimicking small cell carcinoma. doi.org/10.1158/1078-0… Original paper by Sutherland Lab and Jin Ng, PhD doi.org/10.1158/1078-0…

If you like to read final versions - this was just posted:
Commentary on SMARCA4-deficient undifferentiated tumors mimicking small cell carcinoma. 
doi.org/10.1158/1078-0…
Original paper by <a href="/Sutherland_Lab/">Sutherland Lab</a> and <a href="/JinNg_1/">Jin Ng, PhD</a> 
doi.org/10.1158/1078-0…
Stephen V Liu, MD (@stephenvliu) 's Twitter Profile Photo

Press release: phase III ADRIATIC study of durvalumab after chemoradiation for limited stage #SCLC improves both PFS and OS. Follows the PACIFIC approach, randomizing after definitive chemoradiation. Await data on durva + tremelimumab arm. #LCSM astrazeneca.com/media-centre/p…

Press release: phase III ADRIATIC study of durvalumab after chemoradiation for limited stage #SCLC improves both PFS and OS. Follows the PACIFIC approach, randomizing after definitive chemoradiation. Await data on durva + tremelimumab arm. #LCSM

astrazeneca.com/media-centre/p…
Jin Ng, PhD (@jinng_1) 's Twitter Profile Photo

Great to see this #lungcancer screening programme rolled out in London, UK. Looking forward to seeing Australian National Lung Cancer Screening Program being rolled out next year Lung Foundation Australia

Great to see this #lungcancer screening programme rolled out in London, UK. Looking forward to seeing Australian National Lung Cancer Screening Program being rolled out next year <a href="/Lungfoundation/">Lung Foundation Australia</a>
Mohamed I. Saad (@mohamed_i_saad) 's Twitter Profile Photo

Pleased to see this work on patient-derived xenograft methods and protocols published. Thanks to all authors for their valuable contributions to this book! Special thanks to Jin Ng, PhD for the beautiful cover images. Uni of Adelaide South Australian immunoGENomics Cancer Institute Jenkins Lab link.springer.com/book/10.1007/9…

Jin Ng, PhD (@jinng_1) 's Twitter Profile Photo

🔬Our protocol investigating #SCLC transcription factor heterogeneity & robust pipeline to quantify images out now!🔬Sutherland Lab WEHI (Walter and Eliza Hall Institute) link.springer.com/protocol/10.10… Thank you for selecting our pictures for the cover of this book Mohamed I. Saad, super honoured!

🔬Our protocol investigating #SCLC transcription factor heterogeneity &amp; robust pipeline to quantify images out now!🔬<a href="/Sutherland_Lab/">Sutherland Lab</a> <a href="/WEHI_research/">WEHI (Walter and Eliza Hall Institute)</a>

link.springer.com/protocol/10.10…

Thank you for selecting our pictures for the cover of this book <a href="/Mohamed_I_Saad/">Mohamed I. Saad</a>, super honoured!
Jin Ng, PhD (@jinng_1) 's Twitter Profile Photo

Stoked to get an invited spot speaking about our work on gamma delta T cells and #SCLC at Immuno-Oncology 2024 in London Cambridge Healthtech Institute Very cool emerging therapeutics on making immune-"cold" solid tumours, "hot". Thanks The CASS Foundation for the Travel Award towards this

Stoked to get an invited spot speaking about our work on gamma delta T cells and #SCLC at Immuno-Oncology 2024 in London <a href="/CHI_Healthtech/">Cambridge Healthtech Institute</a> 

Very cool emerging therapeutics on making immune-"cold" solid tumours, "hot".  

Thanks The CASS Foundation for the Travel Award towards this
Jarushka Naidoo (@drjnaidoo) 's Twitter Profile Photo

Interesting multi-omic analysis of previously classified SCLC cell lines (YAP1+), identifies that these tumors represent diseases that ‘mimic’ SCLC- in this case- SMARCA4-deficient thoracic tumors, that have a poor prognosis Clinical Cancer Research OncoAlert #LCSM aacrjournals.org/clincancerres/…

Misty Dawn Shields (@drshieldsmd) 's Twitter Profile Photo

Groundbreaking study by Sutherland Lab and colleagues challenging the dogma of “YAP1” neuroendocrine subtype in #SCLC. This research finally clarifies how YAP1+ actually appears in SMARCA4-deficient undifferentiated thoracic tumors, not in #SCLC. #LCSM #researchcurescancer

Jin Ng, PhD (@jinng_1) 's Twitter Profile Photo

First grant as CIA unlocked! Very fortunate to receive this grant from The CASS Foundation towards generating SCLC patient-derived organoids for personalised therapy approaches.

Natasha Rekhtman MD PhD (@natasharekhtman) 's Twitter Profile Photo

1 Hot off the press from team Memorial Sloan Kettering Cancer Center in Cancer Discovery! A study solving the puzzle of exceptional new lung cancer type: #Chromothripsis-mediated Small Cell Lung Cancer #SCLC This took nearly a decade and 42 coauthors to unravel. Here are some highlights 👇

Jin Ng, PhD (@jinng_1) 's Twitter Profile Photo

Immune cell landscape changes upon gender affirming hormone therapy. Considerations for trans/gender-diverse patients receiving any sort of standard of care very important. 🏳️‍⚧️🏳️‍⚧️🏳️‍⚧️